The comorbidity between ADHD and substance use disorders (SUDs) is well-established and bidirectional. People with ADHD are significantly more likely to develop problematic substance use, and untreated ADHD makes substance use treatment less effective. The relationship is driven by shared neurobiology, impulsivity, and self-medication patterns.
Prevalence
Adolescents with ADHD have approximately three times the risk of developing drug use disorders compared to those without ADHD (Sundquist et al. 2015). ADHD individuals are twice as likely to have lifetime nicotine use. The elevated risk extends across all substance classes - alcohol, cannabis, cocaine, and other drugs - not just stimulants.
Comorbid conduct disorder (CD) or oppositional defiant disorder (ODD) further amplifies the risk. These externalising conditions share overlapping genetic and neurobiological pathways with both ADHD and substance use, creating a compounding vulnerability.
The Dopamine Connection
ADHD and substance use disorders share a common neurobiological substrate: the dopaminergic reward system.
In ADHD, dopamine signalling in reward circuits is reduced. This produces the characteristic pattern of sensation-seeking, poor impulse control, and difficulty sustaining motivation toward delayed rewards. The brain is, in effect, under-stimulated by ordinary activities.
Substances of abuse directly target these same reward pathways. Drugs produce the dopamine surge that the ADHD brain struggles to generate from everyday activities. This creates a neurochemical logic to substance use that goes beyond choice or willpower.
The genetic evidence supports this connection. GWAS data show positive genetic correlations between ADHD and alcohol dependence, smoking, and cannabis use. ADHD polygenic risk scores (PRS) are associated with substance misuse, particularly in females (Wimberley et al. 2020). A broader "externalising" genetic factor encompasses ADHD, conduct disorder, and SUD, with shared variants affecting dopaminergic and serotonergic pathways. Mendelian Randomisation analyses suggest ADHD may causally increase risk of some substance use outcomes, not merely correlate with them.
The Self-Medication Hypothesis
Many individuals with ADHD report using substances specifically to manage symptoms. This is not a post-hoc rationalisation - the pharmacological profiles of the substances align with the deficits they are reportedly used to address.
Cannabis is commonly used for sleep difficulties, anxiety, and emotional regulation - all areas where ADHD creates significant impairment. Nicotine is a genuine cognitive enhancer acting through nicotinic receptors, and many people with ADHD report that smoking improves their concentration. Alcohol is used to manage social anxiety and emotional dysregulation. Even cocaine and other stimulants can produce a paradoxically calming effect in ADHD, similar to the therapeutic action of prescribed stimulants.
The problem is that self-medication creates a vicious cycle. The substance provides temporary symptom relief, which reinforces use. Dependence develops. Withdrawal then worsens the original ADHD symptoms, driving further use. Heavy cannabis use, for example, worsens cognitive function and motivation over time - exactly the domains already impaired by ADHD.
Impulsivity as a Mechanism
Beyond self-medication, the impulsivity that defines ADHD is itself a risk factor for substance use. Poor inhibitory control - a core ADHD feature - reduces the ability to resist drug offers or to stop after initial experimentation. Delay aversion, the preference for immediate reward over delayed consequences, makes the immediate high of substance use more compelling than the abstract knowledge that dependence is harmful.
Research suggests that impulsivity in adolescence is a stronger predictor of later SUD than hyperactivity. This distinction matters clinically, because the inattentive presentation of ADHD, despite being less obviously disruptive, still carries substantial impulsivity-related risk.
Adolescent Vulnerability
Adolescence represents the highest-risk period for the ADHD-SUD connection. The adolescent brain is characterised by a mature limbic system (reward and motivation) combined with an immature prefrontal cortex (executive control). This developmental mismatch is present in all adolescents but is amplified in ADHD, where prefrontal development is already delayed.
ADHD-specific risks compound this: school failure, social rejection, chronic boredom, and low self-esteem all push toward substance use as coping. Adolescents with ADHD tend to experiment with substances earlier than their peers, and their risk-taking extends beyond substance use to include higher rates of teenage pregnancy and sexually transmitted infections.
Assessment Challenges
Diagnosing ADHD in the context of active substance use is complicated. Stimulant intoxication can mimic hyperactivity. Withdrawal from various substances can mimic inattention. Cannabis withdrawal produces irritability, sleep disruption, and concentration difficulties that overlap heavily with baseline ADHD symptoms.
Conversely, ADHD can be missed in SUD treatment settings. A patient presenting for alcohol treatment whose underlying ADHD is unrecognised will likely have poorer outcomes, because the impulsivity and executive dysfunction driving their substance use remain unaddressed. Accurate assessment requires careful longitudinal evaluation, ideally with collateral history from family members who can describe the individual's functioning before substance use began.
Treatment Approaches
Treatment of the ADHD-SUD dual diagnosis requires integrated approaches - addressing both conditions simultaneously rather than sequentially.
Importantly, treating ADHD can actually reduce substance use by removing the need to self-medicate. There is no evidence that appropriate stimulant treatment increases substance use disorder risk. In fact, the data suggest a protective effect.
The Core Principle
ADHD and substance use disorders share dopaminergic reward neurobiology and genetic liability. The relationship is driven by impulsivity, sensation-seeking, and self-medication. Untreated ADHD undermines SUD treatment, and SUD worsens ADHD symptoms. Effective management requires treating both conditions together, with medication choices guided by the individual's current substance use status and diversion risk.
References
- Sundquist, J. et al. (2015). ADHD and risk for drug use disorders. Acta Psychiatrica Scandinavica, 132(4), 315-325.
- Wimberley, T. et al. (2020). Genetic liability to ADHD and substance use disorders in individuals with ADHD. Addiction, 115(7), 1368-1377.
- Stanford, S.C. & Sciberras, E. (Eds.) (2022). New Discoveries in the Behavioral Neuroscience of ADHD. Springer.
- Barkley, R.A. (Ed.) (2024). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (4th ed.). Guilford Press.